The way I see it Hepa could still use the financial input of RVX no matter how long it takes us to pay them back. Maybe something is going to happen with the Middle East and there was some substance to the reasoning of that report from the University of Qatar. Hepa wins in every instance of any headway that RVX makes. We are reducing Hepa's risk every day we stay alive. We have seen BTI and others go by the wayside. We know that biotech is the single highest unleaveraged risk investment that can be made. Hepa knows this too. They could wait a lot longer for the technology to be derisked further before acting on their debenture rights. Either way Hepa still retains the distribution rights to China and the territories.

It doesn't seem to make a lot of sense for Hepa to take action at this time and assume all of the associated risks. That's not to say that Hepa might have a different view when enough derisking has been done.

tada